Published on 29 Apr 2024 on GuruFocus.com via Yahoo Finance
Novo Nordisk: Growth Is Still A Better Choice
Novo Nordisk A/S (NYSE:NVO) is the largest Danish pharmaceutical company focusing on developing medicines to combat obesity, diabetes, cardiovascular diseases and non-alcoholic steatohepatitis.
Since the beginning of 2024, the company's share price has risen more than 20% thanks to hype around the new wave of weight loss agents, as well as excellent financial results for the fourth quarter of 2023. Earnings per share for the three months ended Dec. 31 amounted to 71 cents, an increase of 61.40% year over year and beating analysts' expectations by 5 cents.